Predictive Role of Soluble B‐Cell Maturation Antigen in Short‐Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study
The data provide interesting insights into the usefulness of sBCMA as a non-invasive tool for early assessment of treatment efficacy. Its simple and cost-effective detection in peripheral blood could provide clinicians with an addiotional resource for monitoring disease progression and tailoring treatment strategies.
Authors
- Sara Galimberti (ORCID: https://orcid.org/0000-0002-4620-0038)
- Silvia Ursino
- Gabriele Buda (ORCID: https://orcid.org/0000-0002-5240-5611)
- Alice Botti
- Aldo Paolicchi (ORCID: https://orcid.org/0000-0002-9940-8481)
- Maria Livia Del Giudice (ORCID: https://orcid.org/0000-0003-4291-8875)
- Laura Caponi (ORCID: https://orcid.org/0000-0001-9597-9749)
- Alberto Gennari
Institutions
- University of Pisa (IT)
Publication Details
- Journal
- Journal of Clinical Laboratory Analysis
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1002/jcla.25151
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Pfizer